search
Back to results

Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA (TALC)

Primary Purpose

Hiv, Alcohol Problem

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Alcohol Brief Intervention (BI)
Common Elements Treatment Approach (CETA) via Telemedicine
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hiv focused on measuring HIV Outcomes, Unhealthy Alcohol Use, Mental Health, Medication Adherence

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older
  • Living with HIV infection
  • Receiving HIV care at 1 of 4 participating AQMG sites (Alabama Quality Management Group sites - i.e. Ryan White HIV/AIDS Program-funded community clinics in Alabama)
  • Unhealthy alcohol use documented on the AUDIT survey delivered via PRO (i.e. 4 or greater points for women and greater than 8 points for men).

Exclusion Criteria:

  • Inability to use a mobile phone due to cognitive or physical impairments
  • Unable to speak sufficient English to provide informed consent and receive cognitive behavioral therapy
  • Active suicidality or psychosis
  • Risk for acute alcohol withdrawal or seizures

Sites / Locations

  • Health Service CenterRecruiting
  • UAB Family ClinicRecruiting
  • ThriveRecruiting
  • Five HorizonsRecruiting
  • Unity WellnessRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Alcohol Brief Intervention (BI)

Common Elements Treatment Approach (CETA) via Telemedicine

Arm Description

At the time of trial enrollment, participants will receive a session of alcohol brief intervention (BI) via telephone.

Participants will be provided with 6 to 12 weekly CETA sessions via telephone.

Outcomes

Primary Outcome Measures

Change from Baseline Alcohol Use at 6 months
Defined by the participant's score on the Alcohol Use Disorders Identification Test (AUDIT). The minimum score on the AUDIT measure is 0, and the maximum score on the AUDIT measure is 40. For women, a score of of 4 or greater indicates hazardous or harmful alcohol consumption. For men, a score of 8 or greater indicates hazardous or harmful alcohol consumption. Higher scores on the AUDIT measure indicates more hazardous or harmful alcohol consumption.
Change from Baseline Alcohol Use at 6 months
Defined by the participant's blood level of phosphatidylethanol (PEth). Participants will undergo a finger prick to collect a blood sample which will be analyzed for PEth level. PEth level of less than 20 ng/mL indicates abstinence or light drinking (from not drinking to averaging less than two drinks/day for several days a week). PEth level of 20-200 ng/mL indicates moderate level of drinking (averaging between 2 to 4 drinks/day for several days a week). Higher levels of PEth in the blood indicate more hazardous or harmful alcohol consumption.

Secondary Outcome Measures

Change from Baseline Substance Use at 6 months
Defined by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). The minimum score on each substance (i.e. tobacco, alcohol, cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, or other substances) is 0 to 3 (Low health risk). Moderate health risk is defined as a score of 4-26. High heath risk is defined as a score of 27 and higher. Higher scores indicate greater risk for health issues as a result of substance use.
Change from Baseline Substance Use at 12 months
Defined by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). The minimum score on each substance (i.e. tobacco, alcohol, cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, or other substances) is 0 to 3 (Low health risk). Moderate health risk is defined as a score of 4-26. High heath risk is defined as a score of 27 and higher. Higher scores indicate greater risk for health issues as a result of substance use.
Change from Baseline Depression at 6 months
Defined by the Patient Health Questionnaire-9 (PHQ9) validated tool. The minimum score on this measure is 0 and the maximum score on this measure is 27. Higher scores on this measure indicates a worse outcome.
Change from Baseline Depression at 12 months
Defined by the Patient Health Questionnaire-9 (PHQ9) validated tool. The minimum score on this measure is 0 and the maximum score on this measure is 27. Higher scores on this measure indicate a worse outcome.
Change from Baseline Anxiety at 6 months
Defined by the Generalized Anxiety Disorder-7 Item (GAD-7) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 21. Higher scores on this measure indicate a worse outcome.
Change from Baseline Anxiety at 12 months
Defined by the Generalized Anxiety Disorder-7 Item (GAD-7) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 21. Higher scores on this measure indicate a worse outcome.
Change from Baseline Traumatic Stress at 6 months
Defined by the Post-Traumatic Stress Disorder (PTSD) Checklist for DSM-IV (PCL-4) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 80. Higher scores on this measure indicate a worse outcome.
Change from Baseline Traumatic Stress at 12 months
Defined by the Post-Traumatic Stress Disorder (PTSD) Checklist for DSM-IV (PCL-4) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 80. Higher scores on this measure indicate a worse outcome.
Change from Baseline HIV Suppression at 6 months
Defined by Viral Load <20 copies per mL. This testing will be done by the participant's physician and reported to study staff.
Change from Baseline HIV Suppression at 12 months
Defined by Viral Load <20 copies per mL. This testing will be done by the participant's physician and reported to study staff.

Full Information

First Posted
May 26, 2021
Last Updated
August 9, 2023
Sponsor
University of Alabama at Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT04955795
Brief Title
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
Acronym
TALC
Official Title
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using Common Elements Treatment Approach
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 4, 2023 (Actual)
Primary Completion Date
September 30, 2026 (Anticipated)
Study Completion Date
September 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is designed to examine the efficacy of a brief intervention plus a cognitive-behavioral intervention compared to brief intervention alone to address unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among people living with HIV in Alabama.
Detailed Description
Participants will be randomly assigned to receive either Alcohol Brief Intervention (BI) or BI plus Common Elements Treatment Approach (T-CETA) via telephone. Participants will receive either 1 phone session of BI or 6 to 12 weekly phone sessions of BI + T-CETA. Follow ups will occur at 6 and 12 months with participants. Participants will provide data on alcohol use, mental health comorbidities, HIV outcomes, medication adherence, and laboratory collections (CD4+ T cell count, viral load, and an alcohol biomarker: PEth) at the baseline assessment and again at the 6 and 12 month follow ups. The study will also conduct mixed methods implementation measures with a subset of participants who are selected across various strata (i.e. gender, age, trial arm).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hiv, Alcohol Problem
Keywords
HIV Outcomes, Unhealthy Alcohol Use, Mental Health, Medication Adherence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
308 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Alcohol Brief Intervention (BI)
Arm Type
Active Comparator
Arm Description
At the time of trial enrollment, participants will receive a session of alcohol brief intervention (BI) via telephone.
Arm Title
Common Elements Treatment Approach (CETA) via Telemedicine
Arm Type
Experimental
Arm Description
Participants will be provided with 6 to 12 weekly CETA sessions via telephone.
Intervention Type
Behavioral
Intervention Name(s)
Alcohol Brief Intervention (BI)
Intervention Description
The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
Intervention Type
Behavioral
Intervention Name(s)
Common Elements Treatment Approach (CETA) via Telemedicine
Intervention Description
CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
Primary Outcome Measure Information:
Title
Change from Baseline Alcohol Use at 6 months
Description
Defined by the participant's score on the Alcohol Use Disorders Identification Test (AUDIT). The minimum score on the AUDIT measure is 0, and the maximum score on the AUDIT measure is 40. For women, a score of of 4 or greater indicates hazardous or harmful alcohol consumption. For men, a score of 8 or greater indicates hazardous or harmful alcohol consumption. Higher scores on the AUDIT measure indicates more hazardous or harmful alcohol consumption.
Time Frame
6 months
Title
Change from Baseline Alcohol Use at 6 months
Description
Defined by the participant's blood level of phosphatidylethanol (PEth). Participants will undergo a finger prick to collect a blood sample which will be analyzed for PEth level. PEth level of less than 20 ng/mL indicates abstinence or light drinking (from not drinking to averaging less than two drinks/day for several days a week). PEth level of 20-200 ng/mL indicates moderate level of drinking (averaging between 2 to 4 drinks/day for several days a week). Higher levels of PEth in the blood indicate more hazardous or harmful alcohol consumption.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Change from Baseline Substance Use at 6 months
Description
Defined by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). The minimum score on each substance (i.e. tobacco, alcohol, cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, or other substances) is 0 to 3 (Low health risk). Moderate health risk is defined as a score of 4-26. High heath risk is defined as a score of 27 and higher. Higher scores indicate greater risk for health issues as a result of substance use.
Time Frame
6 months
Title
Change from Baseline Substance Use at 12 months
Description
Defined by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). The minimum score on each substance (i.e. tobacco, alcohol, cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, or other substances) is 0 to 3 (Low health risk). Moderate health risk is defined as a score of 4-26. High heath risk is defined as a score of 27 and higher. Higher scores indicate greater risk for health issues as a result of substance use.
Time Frame
12 months
Title
Change from Baseline Depression at 6 months
Description
Defined by the Patient Health Questionnaire-9 (PHQ9) validated tool. The minimum score on this measure is 0 and the maximum score on this measure is 27. Higher scores on this measure indicates a worse outcome.
Time Frame
6 months
Title
Change from Baseline Depression at 12 months
Description
Defined by the Patient Health Questionnaire-9 (PHQ9) validated tool. The minimum score on this measure is 0 and the maximum score on this measure is 27. Higher scores on this measure indicate a worse outcome.
Time Frame
12 months
Title
Change from Baseline Anxiety at 6 months
Description
Defined by the Generalized Anxiety Disorder-7 Item (GAD-7) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 21. Higher scores on this measure indicate a worse outcome.
Time Frame
6 months
Title
Change from Baseline Anxiety at 12 months
Description
Defined by the Generalized Anxiety Disorder-7 Item (GAD-7) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 21. Higher scores on this measure indicate a worse outcome.
Time Frame
12 months
Title
Change from Baseline Traumatic Stress at 6 months
Description
Defined by the Post-Traumatic Stress Disorder (PTSD) Checklist for DSM-IV (PCL-4) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 80. Higher scores on this measure indicate a worse outcome.
Time Frame
6 months
Title
Change from Baseline Traumatic Stress at 12 months
Description
Defined by the Post-Traumatic Stress Disorder (PTSD) Checklist for DSM-IV (PCL-4) validated tool. The minimum score of this measure is 0, and the maximum score of this measure is 80. Higher scores on this measure indicate a worse outcome.
Time Frame
12 months
Title
Change from Baseline HIV Suppression at 6 months
Description
Defined by Viral Load <20 copies per mL. This testing will be done by the participant's physician and reported to study staff.
Time Frame
6 months
Title
Change from Baseline HIV Suppression at 12 months
Description
Defined by Viral Load <20 copies per mL. This testing will be done by the participant's physician and reported to study staff.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older Living with HIV infection Receiving HIV care at 1 of 4 participating AQMG sites (Alabama Quality Management Group sites - i.e. Ryan White HIV/AIDS Program-funded community clinics in Alabama) Unhealthy alcohol use documented on the AUDIT survey delivered via PRO (i.e. 4 or greater points for women and greater than 8 points for men). Exclusion Criteria: Inability to use a mobile phone due to cognitive or physical impairments Unable to speak sufficient English to provide informed consent and receive cognitive behavioral therapy Active suicidality or psychosis Risk for acute alcohol withdrawal or seizures
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jahmil Harriette, Psy.D.
Phone
205-975-4204
Email
jharriette@uabmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen Cropsey, Psy.D.
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
Health Service Center
City
Anniston
State/Province
Alabama
ZIP/Postal Code
36201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jahmil Harriette, Psy.D.
Phone
205-975-4204
Email
jharriette@uabmc.edu
Facility Name
UAB Family Clinic
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jahmil Harriette
Email
jharriette@uabmc.edu
First Name & Middle Initial & Last Name & Degree
Karen Cropsey
Email
kcropsey@uabmc.edu
Facility Name
Thrive
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jahmil Harriette, Psy.D.
Phone
205-975-4204
Email
jharriette@uabmc.edu
Facility Name
Five Horizons
City
Montgomery
State/Province
Alabama
ZIP/Postal Code
36111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jahmil Harriette
Phone
205-975-4204
Email
jharriette@uabmc.edu
Facility Name
Unity Wellness
City
Opelika
State/Province
Alabama
ZIP/Postal Code
36801
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jahmil Harriette, Psy.D.
Phone
205-975-4204
Email
jharriette@uabmc.edu

12. IPD Sharing Statement

Learn more about this trial

Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA

We'll reach out to this number within 24 hrs